CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 2, 2019 at 8:00 A.M. ET to report its first quarter 2019 financial results and to discuss recent business updates.
The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 5968036. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a
biopharmaceutical company committed to developing novel medicines to
transform the lives of patients with life-altering central nervous
system (CNS) disorders. Sage’s portfolio of novel compounds targets
critical receptor systems in the brain and includes the first treatment
specifically approved by the U.S. Food and Drug Administration for
postpartum depression as well as compounds being developed as potential
treatments for diseases such as major depressive disorder, insomnia,
bipolar disorder and essential tremor. For more information, please
visit www.sagerx.com.